Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Indotecan - Gibson Oncology

Next Previous
Drug Profile

Indotecan - Gibson Oncology

Alternative Names: LMP-400; NSC-724998; NSC-743400

Latest Information Update: 28 Jul 2024

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Linus Oncology; National Cancer Institute (USA); Purdue University
  • Developer Gibson Oncology; National Cancer Institute (USA)
  • Class Anti-inflammatories; Antiasthmatics; Antineoplastics; Antirheumatics; Eye disorder therapies; Isoquinolines; Small molecules
  • Mechanism of Action DNA topoisomerase I inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Phase II Colorectal cancer; Ewing's sarcoma; Solid tumours
  • Discontinued Lymphoma

Most Recent Events

  • 28 Jul 2024 No recent reports of development identified for phase-I development in Solid-tumours(Late-stage disease, Second-line therapy or greater) in USA (IV, Infusion)
  • 04 Jan 2022 Indotecan - Gibson Oncology is available for licensing as of 04 Jan 2022. https://gibsononcology.com/our-pipeline/
  • 24 Jun 2021 Phase-I clinical trials in Solid tumours is ongoing in USA (Gibson Oncology pipeline, June 2021)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top